Market Research Logo

Checkpoint Therapeutics Inc (CKPT) - Financial and Strategic SWOT Analysis Review

Checkpoint Therapeutics Inc (CKPT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Checkpoint Therapeutics Inc (Checkpoint Therapeutics), a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops and commercializes non-chemotherapy and immune enhanced combination treatments for the treatment of solid tumor cancers. The company’s lead product candidate, CK-301 human antagonistic antibody intended for the treatment of patients with non-small cell lung cancer (NSCLC) and other solid tumors. Its other pipeline products includes a portfolio of human immuno-oncology agents and targeted anti-cancer agents intended for the treatment of multiple types of cancer including renal cell carcinoma, EGFR mutation-positive NSCLC and multiple forms of cancer. The company also works in partnership with other pharmaceutical companies to co-develop its antibodies. Checkpoint Therapeutics is headquartered in New York, the US.

Checkpoint Therapeutics Inc Key Recent Developments

May 10,2018: Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Mar 15,2018: Checkpoint Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
Jan 11,2018: Adimab Initiates Update on Clinical Progression of Partner Programs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Checkpoint Therapeutics Inc - Key Facts
Checkpoint Therapeutics Inc - Key Employees
Checkpoint Therapeutics Inc - Key Employee Biographies
Checkpoint Therapeutics Inc - Major Products and Services
Checkpoint Therapeutics Inc - History
Checkpoint Therapeutics Inc - Company Statement
Checkpoint Therapeutics Inc - Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Checkpoint Therapeutics Inc - Business Description
Checkpoint Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Checkpoint Therapeutics Inc - Strengths
Checkpoint Therapeutics Inc - Weaknesses
Checkpoint Therapeutics Inc - Opportunities
Checkpoint Therapeutics Inc - Threats
Checkpoint Therapeutics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Checkpoint Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 10, 2018: Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Checkpoint Therapeutics Inc, Key Facts
Checkpoint Therapeutics Inc, Key Employees
Checkpoint Therapeutics Inc, Key Employee Biographies
Checkpoint Therapeutics Inc, Major Products and Services
Checkpoint Therapeutics Inc, History
Checkpoint Therapeutics Inc, Key Competitors
Checkpoint Therapeutics Inc, Ratios based on current share price
Checkpoint Therapeutics Inc, Annual Ratios
Checkpoint Therapeutics Inc, Annual Ratios (Cont...1)
Checkpoint Therapeutics Inc, Interim Ratios
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Checkpoint Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Checkpoint Therapeutics Inc, Performance Chart (2015 - 2017)
Checkpoint Therapeutics Inc, Ratio Charts
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Checkpoint Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report